CD274 and melanoma: A study by del Re et al. examined plasma derived EVs in 8 NSCLC patients and 18 melanoma patients that received Nivolumab or Pembrolizumab and performed ddPCR to measure PD-L1 mRNA levels within these vesicles [124].